Summary

Hemostasis and Tissue Sealing Agents Market Research Report Information by Product (Topical Hemostat, Adhesive & Tissue Sealant), By Material (Chitosan-based Products, Mineral based Products), By Application (Trauma, General Surgery, Minimally Invasive Surgery, Gynecology Others), By End-User (Hospitals, Ambulatory Surgical Centers, Research Institutes), and Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
Market Overview
In 2023, the market size of hemostasis and tissue sealing agents was estimated to be USD 8.39 billion. During the forecast period (2024-2032), the Hemostasis and Tissue Sealing Agents Market industry is anticipated to experience a compound annual growth rate (CAGR) of 8.04%, increasing from USD 9.02 billion in 2024 to USD 18.19 billion by 2032. The market is being driven by the increasing prevalence of chronic blood disorders and road accidents, the global preference for minimally invasive procedures, and the aging population.
Another factor that is driving the market's growth is the increasing prevalence of chronic blood disorders. Due to impaired clotting factors, individuals with specific blood disorders, including hemophilia or von Willebrand disease, are at an elevated risk of hemorrhaging. It may be necessary for individuals with these disorders to use hemostasis agents during surgical procedures or medical interventions, as they facilitate blood clotting and control hemorrhage. For example, the 2022 update from the International Society on Thrombosis and Hemostasis indicates that approximately 10 million cases of venous thromboembolism occur annually on a global scale. Deep vein thrombosis (DVT) is responsible for the deaths of 544,000 individuals in Europe each year, as per the same source.

Market segment insights
The market is segmented into Topical hemostats and adhesive and tissue sealants comprise market segmentation by product.
The market segmentation is predicated on a material that encompasses mineral-based products and chitosan-based products.
Hospitals, ambulatory surgical centers, and research institutes comprise the market segmentation, which is predicated on end-users.
Regional Perspectives
The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Hemostasis and Tissue Sealing Agents market held the largest market share. This is a result of the ongoing advancements in medical technology, the growing prevalence of chronic diseases, and the geriatric population. The market has become a center for research and development, resulting in the introduction of innovative products with superior efficacy, with a concentration on improving patient outcomes and reducing postoperative complications.
The European Hemostasis and Tissue Sealing Agents market is anticipated to have the second-largest market share, because of the trend toward the integration of Hemostasis and tissue sealing agents, including counseling, and favorable health policies. In addition, the German Hemostasis and Tissue Sealing Agents market was identified as having the largest market share, while the French Hemostasis and Tissue Sealing Agents market is anticipated to experience the quickest growth in the European region.
It is anticipated that the Asia-Pacific Hemostasis and Tissue Sealing Agents market will experience the most rapid growth from 2024 to 2032. This is the result of a growing middle class, accelerated economic growth, and increased urbanization. The demand for healthcare, technology, and consumer products is driven by the region's growing population. Industrial growth and innovation are stimulated by robust investments in infrastructure, education, and technology.
The Middle East, Africa, and Latin America comprise the Rest of the World. The primary factors that influence the growth of Hemostasis and Tissue Sealing Agents in the Middle East and Africa. The Middle East and Africa region has encountered The demand for sophisticated medical products is being driven by the expansion of healthcare infrastructure and the increase in healthcare expenditure.

The primary market players
Johnson & Johnson (US), B Braun Medical Inc (Germany), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), and Pfizer Inc (US) are the primary players in the market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research Data Flow:
3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Technique
3.8 DATA MODELLING
3.8.1 Microeconomic Factor Analysis:
3.8.2 Data Modelling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.1 DRIVERS
4.1.1 Growing Incidences Of Road Accidents And Chronic Blood Disorders
4.1.2 Growing Preference Of Minimally Invasive Procedures
4.2 RESTRAINTS
4.2.1 High Costs and Stringent Regulatory Requirements
4.3 OPPORTUNITY
4.3.1 Growing Incidences Of Road Accidents And Growing Geriatric Population
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 Research & Development
5.1.2 Manufacturing
5.1.3 Distribution
5.1.4 Marketing & Sales
5.1.5 Post-Sales Monitoring
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 bargaining power of buyers
5.2.2 Bargaining Power of Suppliers
5.2.3 Threat of New Entrants
5.2.4 THREAT OF SUBSTITUTES
5.2.5 Intensity of Rivalry
5.3 IMPACT OF COVID-19
5.4 HEMOSTASIS AND TISSUE SEALING AGENTS FOR MILITARY PURPOSE
6 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 TOPICAL HEMOSTAT
6.2.1 Active
6.2.2 Mechanical
6.2.3 Flowable
6.3 ADHESIVE & TISSUE SEALANT
6.3.1 Synthetic Tissue Sealant
6.3.2 Natural Tissue Sealant
6.3.3 Adhesion Barrier Products
7 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY MATERIAL
7.1 OVERVIEW
7.2 CHITOSAN-BASED PRODUCTS
7.3 MINERAL BASED PRODUCTS
8 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 TRAUMA
8.2.1 Burns
8.2.2 Accidents
8.2.2.1 Major Accidents
8.2.2.2 Minor Accidents
8.2.3 Others
8.3 GENERAL SURGERY
8.4 MINIMALLY INVASIVE SURGERY
8.5 GYNAECOLOGY
8.6 OTHERS
9 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.2.1 Public
9.2.2 Private
9.2.3 Military
9.3 AMBULATORY SURGICAL CENTERS
9.3.1 Independent Ambulatory Surgical Centers
9.3.2 Military Ambulatory Surgical Centers
9.4 RESEARCH INSTITUTES
10 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 spain
10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
10.5.1 Middle East & Africa
10.5.2 South America
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2022
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 product launch / Product approval
11.6.2 Acquisition
12 COMPANY PROFILES
12.1 JOHNSON & JOHNSON SERVICES, INC
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 productS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 B. BRAUN SE
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 products OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 MIL LABORATORIES PVT. LTD
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 productS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 BECTON, DICKINSON, AND COMPANY
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 PFIZER INC.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 TELEFLEX INCORPORATED
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 TELEFLEX INCORPORATED: kEY DEVELOPMENTS
12.6.6 KEY STRATEGIES
12.7 MEDTRONIC
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 BAXTER
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 MEDTRADE PRODUCTS LIMITED
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 AXIO BIOSOLUTIONS PVT LTD
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 DATA CITATIONS